Results 241 to 250 of about 185,884 (310)
The Economic Burden of Atherosclerotic Cardiovascular Disease in the Kingdom of Saudi Arabia. [PDF]
Alasnag M, Tash A.
europepmc +1 more source
ABSTRACT It is estimated that a large proportion of drug candidates fail in human clinical trials, mainly because animal models cannot fully replicate human disease and because of differential responses to various medications between humans and animals.
Weiping Ding, Iqra Ilyas, Suowen Xu
wiley +1 more source
Hydrogel‐based drug delivery systems offer a promising approach for treating intracerebral hemorrhage (ICH) by overcoming blood‐brain barrier limitations, enabling precise, sustained release of neuroprotective and anti‐inflammatory agents. These systems enhance treatment efficacy, but challenges remain in biosafety, drug penetration, and scalability ...
Haojun Shi +18 more
wiley +1 more source
Association between Dysgeusia and Atherosclerotic Cardiovascular Disease: A Cross-Sectional Study With Propensity Score-Matched Analyses. [PDF]
Zhou P, Zhou X, Tang S, Liang D, Wu D.
europepmc +1 more source
Macrophage‐derived S100 calcium‐binding protein A9 (S100A9) promotes the pathological progression of pulmonary arterial hypertension (PAH). S100A9 upregulates the interaction between signal‐transducing adaptor protein 2 and leucine‐rich repeat kinase 2, thereby regulating mitochondria–endoplasmic reticulum (ER) contact.
Chen Gong +15 more
wiley +1 more source
Automated Abdominal Aortic Calcification Scores and Atherosclerotic Cardiovascular Disease in the UK Biobank Imaging Study. [PDF]
Sim M +24 more
europepmc +1 more source
A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione +2 more
wiley +1 more source
Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies. [PDF]
Tan SH, Wu JL, Zhuo SX, Zhang Y, Wang M.
europepmc +1 more source

